Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
PORT-3
i
Other names:
PORT-3, IMM65, invariant natural killer T-cells therapeutics, IMM60/NY-ESO-1 immunogenic peptides, PRECIOUS-01, iNKT therapeutics
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Portage
Drug class:
NY ESO 1 inhibitor
Related drugs:
‹
TAEST16001 (2)
BNT111 (1)
GSK3377794 (1)
TBI-1301 (1)
CMB305 (0)
GSK2241658A (0)
GSK3845097 (0)
GSK3901961 (0)
ID-LV305 (0)
IDC-G305 (0)
LYL132 (0)
LYL331 (0)
MultiTAA T cell therapy (0)
N201 (0)
NY-ESO-1 TCR (0)
NY-ESO-1 TCR-T cell therapy (0)
PDC*lung (0)
TCRT-ESO-A2 (0)
VTP-600 (0)
CDX-1401 (0)
TAEST16001 (2)
BNT111 (1)
GSK3377794 (1)
TBI-1301 (1)
CMB305 (0)
GSK2241658A (0)
GSK3845097 (0)
GSK3901961 (0)
ID-LV305 (0)
IDC-G305 (0)
LYL132 (0)
LYL331 (0)
MultiTAA T cell therapy (0)
N201 (0)
NY-ESO-1 TCR (0)
NY-ESO-1 TCR-T cell therapy (0)
PDC*lung (0)
TCRT-ESO-A2 (0)
VTP-600 (0)
CDX-1401 (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login